00:50 , Jan 5, 2019 |  BC Extra  |  Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
20:41 , Oct 31, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs A panel of five genomic loci could help predict the risk of food allergy. Genome-wide association studies in 1,547 children with food allergies and 4,897 healthy volunteers identified associations between the disease and...
21:37 , Oct 24, 2017 |  BC Extra  |  Preclinical News

GWAS identify new risk loci in allergies and breast cancer

Three genome-wide association studies (GWAS) have identified new genetic markers associated with an increased risk of food allergies and breast cancer. In a paper published in Nature Communications , researchers at the Max Delbrueck Center...
23:46 , Sep 19, 2017 |  BC Extra  |  Company News

Management tracks: OncoMed, Vividion, Spero

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman and CEO Paul Hastings began a medical leave of absence. Proteomics company Vividion Therapeutics Inc. (San Diego, Calif.) named Diego Miralles CEO. He was president of the...
21:33 , Dec 16, 2016 |  BioCentury  |  Emerging Company Profile

Floral delivery

Instability and poor penetration can make topical delivery of proteins and peptides into the skin inefficient and inconsistent. Azitra Inc. is using an engineered human commensal strain of bacteria to consistently deliver therapeutic proteins to...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Company News

Medivir, Daewoong Pharmaceutical deal

Medivir said it and Daewoong agreed to discontinue development of MIV-210 to treat HBV infection. Medivir said that although MIV-210 has a "proven competitive antiviral effect," it does not remove the infection completely. The partners...
07:00 , Mar 22, 2010 |  BC Week In Review  |  Company News

Medivir, Daewoong Pharmaceutical, Hainan Noken Pharmaceutical Industry deal

Daewoong assumed exclusive rights to develop and commercialize Medivir's MIV-210 (lagociclovir valactate) in South Korea, Japan and China from Hainan. Medivir retains rights elsewhere. The nucleoside analog prodrug of 3'-fluoro-2', 3'-dideoxyguanosine (FLG) is in Phase...
07:00 , Mar 23, 2009 |  BC Week In Review  |  Company News

IBT Laboratories sales and marketing update

IBT launched its Pneumococcal Antibody Avidity Test to assess the effectiveness of antibodies produced in response to pneumococcal vaccines, ProGenotyper filaggrin mutation detection test to determine whether a patient with atopic dermatitis or ichthyosis vulgaris...
07:00 , Apr 3, 2006 |  BC Week In Review  |  Clinical News

Medivir preclinical data

Researchers published in Antimicrobial Agents and Chemotherapy that MIV-210, a nucleoside analog prodrug of 3'-fluoro-2', 3'-dideoxyguanosine (FLG), was active against both lamivudine- and adefovir-resistant HBV. MIV-210 also is in Phase IIa trials for HIV infection....
03:43 , Mar 22, 2006 |  BC Extra  |  Clinical News

Researchers link skin gene to atopic disease

Researchers from the University of Dundee and colleagues published in Nature Genetics a genetic study that showed that two independent loss-of-function mutations of the gene encoding filaggrin are predisposing factors for atopic dermatitis. Filaggrin is...